Related Experiment Videos
[Pancytopenia during low-dosage methotrexate treatment in patients with rheumatoid arthritis]
1Lillehammer Sanitetsforenings Revmatismesykehus.
Abstract:
Adverse effects are no more common during treatment with low doses of methotrexate than during treatment with conventional anti-rheumatic drugs. Serious events do occur, however, and among the most dangerous is pancytopenia. We describe five patients with this complication. Triggering factors for such adverse events are often interactions with other medication, especially drugs that reduce renal clearance of methotrexate, and also other anti-folate drugs, e.g. trimetoprim. Events that increase the rate of cell formation in the myelopoietic tissue, e.g. infection and haemorrhage, may also increase risk of complications. Use of leukovorin is recommended when bone marrow suppression is suspected.
Insights
Low-dose methotrexate has similar adverse effects to other drugs, but serious complications like pancytopenia can occur. Drug interactions and increased cell formation can heighten risks, necessitating careful monitoring and potential leukovorin use.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Methotrexate is a common treatment for rheumatic diseases.
- While generally safe at low doses, serious adverse effects can arise.
- Pancytopenia is a critical and dangerous complication of methotrexate therapy.
Observation:
- This report details five patients who developed pancytopenia.
- Identified risk factors include interactions with medications affecting renal clearance and co-administration of anti-folate drugs like trimethoprim.
- Increased myelopoietic activity due to infection or hemorrhage also elevates complication risk.
Findings:
- Low-dose methotrexate is not associated with increased adverse effects compared to conventional disease-modifying anti-rheumatic drugs.
- Pancytopenia is a significant, albeit rare, serious adverse event.
- Drug interactions and physiological states impacting cell turnover are key triggers.
Implications:
- Clinicians should be vigilant for pancytopenia in patients on methotrexate.
- Careful medication review is essential to avoid drug interactions.
- Leukovorin rescue therapy is recommended when bone marrow suppression is suspected.